Haleos Labs FY26 profit falls, recommends ₹1.50 dividend

1 min read Updated on 30 May 2026, 03:27 PM

Reviewed by

Ashish TScanX News Team

AI Summary

Haleos Labs Limited reported a decline in net profit to ₹1,777.68 lakh for FY26 from ₹2,137.08 lakh in FY25, with revenue decreasing to ₹30,098.96 lakh. The Board recommended a ₹1.50 dividend and approved the reappointment of a Whole-time Director and statutory auditors, while accepting the resignation of an Independent Director.

*this image is generated using AI for illustrative purposes only.

Haleos Labs Limited reported a net profit of ₹1,777.68 lakh for the financial year ended March 31, 2026, a decline from ₹2,137.08 lakh in the previous year. Revenue from operations for the year stood at ₹30,098.96 lakh, compared to ₹33,337.10 lakh in FY25. The Board of Directors, in its meeting held on May 29, 2026, approved the audited standalone and consolidated financial results and recommended a dividend of ₹1.50 per equity share of ₹10 face value for the year 2025-26, subject to shareholder approval.

Financial Performance

For the quarter ended March 31, 2026, the company reported a net profit of ₹223.46 lakh on revenue from operations of ₹6,338.42 lakh. In the corresponding quarter of the previous year, the net profit was ₹267.51 lakh on revenue of ₹8,542.78 lakh. Total expenses for the year increased to ₹27,721.96 lakh from ₹30,727.55 lakh in the prior year. The statutory auditors, M/s Rambabu & Co., issued an unmodified opinion on the financial results.

Board Decisions and Corporate Actions

The Board approved the reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director for a further period of five years effective from September 2, 2026, subject to shareholder approval. Additionally, the Board accepted the resignation of Mrs. Sundaramma Patibandla as Independent Director, effective from the close of business hours on May 29, 2026. Consequently, the Audit Committee, Nomination & Remuneration Committee, and Stakeholders' Relationship Committee were reconstituted.

Auditor Appointments and Related Party Transactions

The Board approved the appointment of M/s. Suryanarayana & Suresh, Chartered Accountants, as Statutory Auditors for a period of five years, subject to shareholder approval. M/s Annapragada & Co. was reappointed as Cost Auditors for the year 2026-27. The company disclosed related party transactions for the half year ended March 31, 2026, including transactions with Purogene Labs Private Limited and Mahi Drugs Private Limited.

Key Financial Metrics for FY26

Metric	FY26 (₹ in Lakhs)	FY25 (₹ in Lakhs)
Revenue from Operations	30,098.96	33,337.10
Total Revenue	30,241.07	33,731.66
Total Expenses	27,721.96	30,727.55
Profit Before Tax	2,519.11	3,004.11
Net Profit	1,777.68	2,137.08
Earnings Per Share (Basic)	58.80	70.69

Historical Stock Returns for Haleos

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.96%	+3.43%	-7.43%	+11.66%	+26.08%	+131.46%

What strategic initiatives will Haleos Labs implement to reverse the decline in revenue and net profit?

How will the change in statutory auditors impact the company's financial reporting and governance standards?

What are the potential market implications of the resignation of an Independent Director and the reconstitution of key committees?

Read Next Article

Haleos Labs reappoints Sudeepthi Gopineedi as Whole-time Director for 5 years

1 min read Updated on 30 May 2026, 03:45 AM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

AI Summary

Haleos Labs Limited has approved the reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director for a term of five years effective September 2, 2026, pending shareholder approval. The Board's decision follows recommendations from the Audit and Nomination & Remuneration Committees. Gopineedi, who is the daughter of the Managing Director and sister of the Executive Director, has led key quality initiatives since joining the company.

*this image is generated using AI for illustrative purposes only.

Haleos Labs Limited has approved the reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director for a term of five years effective September 2, 2026, ensuring continuity in its leadership structure. The Board of Directors approved the proposal at its meeting held on May 29, 2026, based on the recommendations of the Audit Committee and Nomination & Remuneration Committee. The reappointment is subject to the approval of the shareholders of the Company.

Mrs. Sudeepthi Gopineedi’s current tenure as Whole-time Director concludes on September 1, 2026. The new term will commence on September 2, 2026, for a period of five consecutive years, although she will remain liable to retire by rotation. The Company affirmed that she is not debarred from holding the office of Director by any SEBI order or other regulatory authorities, in compliance with circulars issued by the National Stock Exchange of India Limited and BSE Limited dated June 20, 2018.

Mrs. Sudeepthi Gopineedi is a postgraduate from Birla Institute of Technology and Science, Pilani, with qualifications in Chemistry and Computer Science. Prior to joining Haleos Labs, she gained international experience working with multinational organisations such as Amazon, Oracle, The World Bank, and Blue Cross Blue Shield Association. During her tenure with the Company, she has led key quality and operational initiatives, including the successful completion of regulatory and customer audits.

The filing discloses her familial relationships within the Company's management. She is related to Mr. TVVSN Murthy, the Managing Director, as her father, and Mr. Talluri Venkata Praveen, the Executive Director, as her brother.